Actemra Dosing Frequency for Still's Disease
For adult-onset Still's disease (AOSD), Actemra (tocilizumab) should be administered intravenously at 8 mg/kg every 2 weeks, or subcutaneously at 162 mg weekly for patients ≥100 kg (or every other week for patients <100 kg, with escalation to weekly based on response). 1
Intravenous Dosing
The FDA-approved intravenous regimen for systemic juvenile idiopathic arthritis (sJIA)—which is now recognized as the same disease entity as AOSD 2—specifies:
- Patients <30 kg: 12 mg/kg every 2 weeks
- Patients ≥30 kg: 8 mg/kg every 2 weeks 1
While the FDA label doesn't explicitly list AOSD as a separate indication, the 2024 EULAR/PRES guidelines confirm that sJIA and AOSD are the same disease, differing only by age of onset 3, 2. Clinical trials in AOSD have consistently used 8 mg/kg every 2 weeks intravenously 4, 5.
Subcutaneous Dosing
For subcutaneous administration:
- Patients <30 kg: 162 mg every 2 weeks
- Patients ≥30 kg: 162 mg every week 1
For adults with AOSD specifically, the subcutaneous dosing typically follows the rheumatoid arthritis paradigm: 162 mg weekly for patients ≥100 kg, or every other week for patients <100 kg with escalation to weekly based on clinical response 1.
Evidence from Clinical Practice
The pivotal phase III trial in AOSD used 8 mg/kg intravenously every 2 weeks during the 12-week double-blind phase 4. The long-term extension study continued this same dosing interval, with a mean observation period of 168.9 weeks 5. Notably, 63.6% of patients successfully extended their dosing interval to a mean of 3.4 weeks by the end of the study while maintaining disease control 5.
Real-world case series have reported various regimens:
Key Clinical Considerations
The 2024 EULAR/PRES guidelines strongly recommend prioritizing IL-1 and IL-6 inhibitors (including tocilizumab) over prolonged glucocorticoid use to achieve treatment targets while minimizing steroid-related toxicity 3. The guidelines emphasize that IL-6 inhibitors demonstrate high efficacy for controlling both systemic and articular manifestations of Still's disease 8, 3.
Important Caveats:
- Do not initiate tocilizumab if absolute neutrophil count <2000/mm³, platelets <100,000/mm³, or ALT/AST >1.5× ULN 1
- Maximum single dose: 800 mg per infusion 1
- Tocilizumab may blunt CRP elevation, which can mask disease activity or infection 3
- Infectious adverse events are more common with IL-6 inhibition compared to IL-1 inhibition, with serious adverse event rates of 36.5/100 patient-years for tocilizumab versus 22.6/100 patient-years for IL-1 inhibitors 8
Dosing Interval Extension
After achieving disease control, consider extending the dosing interval as demonstrated in the long-term extension study where the majority of patients successfully transitioned to less frequent dosing while maintaining remission 5. This approach can reduce treatment burden and potentially minimize adverse events while maintaining efficacy.
The subcutaneous formulation offers convenience for long-term management, with case reports supporting 162 mg weekly as effective for refractory AOSD 7, 9.